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An effort was made to elucidate the limits of drug-activity tests in small animals. Human
plasma kinetics of gentamicin, netilmicin, ticarcillin, ceftazidime, and ceftriaxone were
approximated in normal and in granulocytopenic mice infected with various strains of
Pseudomonas aeruginosa in the thigh muscle or intraperitoneally. The effect of such dos-
ing on bacterial time-kill curves and on survival was compared with the effect of identical
amounts of drug given as a single-bolus injection. With fl-lactams, a highly significant
superiority of fractionated dosing (simulated human kinetics) over bolus injections (mu-
rine plasma kinetics) was demonstrated, whereas with aminoglycosides it was a single-
bolus injection that tended to be more active. Thus, when tested in conventional small-
animal models, aminoglycoside activity may be overestimated, whereas fl-lactam activity
may be underestimated in respect to humans. These differences found in vivo most prob-
ably reflect the different pharmacodynamics between aminoglycosides and f3-lactam drugs
(time-kill curves, dose-response curves, and postantibiotic effect) similar to those previ-
ously observed in vitro.
In a first approach, the in vivo activity and toxicity
of any new drug is routinely studied in experimental
models by using small animals such as mice, rats,
guinea pigs, or rabbits. Moreover, some measure of
the activity and toxicity of a single dose has become
a mandatory requirement for any new drug to be
licensed. Although conclusions from such studies are
not directly transferable to man, they are at least
looked on as a basis for investigations to be per-
formed in more expensive animal models or humans.
However, major biologic differences have to be con-
sidered between small experimental animals and
man, one of which is metabolic activity in general.
This difference becomes most evident in a compari-
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son of human vs. small-animal kinetics of many in-
jected drugs. As an example, we found a plasma half-
life in mice of 15 min for penicillin G [1], of 16-20
min for ticarcillin, and of 22 min for gentamicin [2,
3]. In contrast, the half-lives in humans for these
drugs are known to be ,\,0.5, 1.2, and 2 hr for peni-
cillin G, ticarcillin, and gentamicin, respectively [4,
5]. These differences in half-life may explain the very
poor results frequently obtained in small-animal
models, even with antimicrobial agents that have
been shown to be very potent in vitro against the tar-
get organism. Thus, compared with man, much
higher doses of antimicrobial agents have to be given
to small animals to obtain antimicrobial efficacy.
The present study was based on the hypothesis that
the difference between small animals and man re-
garding drug kinetics cannot be overcome by just in-
jecting larger amounts (per kilogram of body weight)
of that substance into small animals. Rather, some
kind of "human-adapted" pharmacokinetics of the
study drug should be approximated in small animals.
In a tentative pioneering effort we used an ex-
perimental thigh infection — as well as the standard
mouse peritonitis model — to elucidate the impact of
murine vs. human half-life of J3-lactam drugs and
aminoglycosides on activity against Pseudomonas
aeruginosa. In one group of mice the study drug was
given as a single-bolus injection that was followed
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by typical murine plasma kinetics of the drug, i.e.,
very high peak levels and a half-life in the order of
15-25 min. In a comparative group of mice the same
total amount of study drug was subdivided and in-
jected as fractional doses such that human plasma
kinetics of the drug were approximated. Antimicro-
bial activity was quantitated by construction of bac-
terial time-kill curves in vivo. For better assessment
of the antimicrobial activity of the drug per se the
studies were performed not only in normal animals
but in granulocytopenic animals as well.
Materials and Methods
Organisms. A clinical isolate of P aeruginosa
designated A10 was the main study organism. Two
strains of P aeruginosa were included in confirma-
tory studies: strain ATCC 27853 (ATCC, Rockville,
Md) and an additional clinical isolate, designated
14974. Clinical isolates were from the Institute of
Medical Microbiology (Bern, Switzerland). In ad-
dition, Escherichia coli strain ATCC 25922 was used
to study ceftriaxone dynamics. All organisms were
susceptible to the study drugs when tested by the
method of Bauer et al. [6] in vitro. MICs and MBCs
in vitro were determined by using the broth-dilution
technique [7] and Mueller-Hinton broth supple-
mented with Ca' and Mg", as suggested by Strat-
ton and Reller [8].
Drugs. Drugs used for the in vitro determina-
tion of MICs and MBCs were standard powders.
Ticarcillin was obtained from Beecham Laborato-
ries (Betchworth, Surrey, U.K.); gentamicin and netil-
micin from Essex AG (Lucerne, Switzerland);
ceftazidime from Glaxo Pharmaceuticals (Green-
ford, Middlesex, U.K.); and ceftriaxone from Hoff-
mann La Roche (Basel, Switzerland). Drugs used for
in vivo studies were commercial products: cy-
clophosphamide (Mead Johnson Pharmaceuticals,
Evansville, Ind), gentamicin and netilmicin (Essex),
ticarcillin (Beecham), ceftazidime (Glaxo), and cef-
triaxone (Roche).
Mice. Female ICR mice weighing 27-30 g each
were obtained from Tierzucht der Universitat (Tier-
spital, Ziirich, Switzerland). Granulocytopenia was
produced as previously reported [2], i.e., by two ip
injections of cyclophosphamide, 150 and 100 mg/kg,
at four days and one day, respectively, before the mice
were infected. Smears from blood and infected thighs
were checked for the presence of granulocytes in
some but not all experiments.
Determinations of plasma drug levels. Blood
was drawn from the retroorbital sinus into heparin-
ized microhematocrit tubes (Clay Adams, Parsip-
pany, NY). A biologic assay [9] using Bacillus subtilis
strain ATCC 6633 (Difco, Detroit) for gentamicin,
netilmicin, and ticarcillin, and E. coli strain ATCC
25922 for ceftazidime and ceftriaxone was performed
for the determination of plasma drug concentrations.
Standard curves were obtained in pooled ICR-mouse
plasma.
Preliminary experiments had shown that peak
drug levels in plasma were obtained by 10-15 min
after sc injections of the study drug. Thus, in main
experiments, peak drug levels were drawn 15 min af-
ter the first drug injection.
Bacterial inocula. Broth cultures of the study or-
ganisms were grown to f‘,108 cfu/ml (estimated by
turbidity, as determined in separate experiments). Be-
fore injection, the study organisms were washed in
ice-cold 0.9% NaCl and resuspended in 0.9% NaCl
to a concentration of 10 8 cfu/ml.
Quantitation of bacterial growth and killing.
Amputated thighs were immediately homogenized
with a Polytron® tissue homogenizer (Kinematica,
Lucerne, Switzerland) in 4 ml of iced saline (8.5 g
of NaCl/liter, 50 mg of Ca"/liter, 200 mg of Mg"/li-
ter) to which 0.1 ml of f3-lactamase (Whatman Bio-
chemicals, Maidstone, Kent, U.K.) was added.
Homogenates were plated in duplicate on tryptic-
soy agar (Becton Dickinson) plates. After 15-18 hr
of incubation, the numbers of cfu were counted and
mathematically transformed into remaining viable
organisms per thigh.
Experimental design in vivo. Thigh infection
model. Two hours before starting the treatment, 0.1
ml of an ice-cold suspension of 10 8 cfu of P aerugi-
nosa/m1 in 0.9% NaCl was injected into the thigh
of slightly ether-anesthetized granulocytopenic or
normal mice. Two groups of mice were treated com-
paratively with one of two regimens in each experi-
ment. (1) a single sc bolus injection of the study drug
(in 0.1 ml of 0.9% NaCl) followed by repeated injec-
tions of 0.9% NaC1 and (2) an identical total amount
of the same study drug subdivided into fractional
decreasing doses and injected sc every 15 min (ticar-
cillin), every 20 min (gentamicin, netilmicin, or
ceftazidime), or every 30 min (ceftriaxone). Control
mice received repeated injections of 0.9% NaCl in-
stead of the study drug, as did the mice treated ac-
cording to the first regimen. In each experiment,
blood was drawn every 20-60 min from at least three
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Figure 1. Human vs. murine plasma kinetics of ticar-
cillin and activity against P. aeruginosa A10 in vivo. Each
data point in growth and kill curves (top and center top)
represents the geometric mean value of three to five mice
± 1 SD. Data points in center bottom panel stand for
the mean value ± 1 SD of plasma level determinations
from three to six mice (compiled from experiments shown
in top and center top panels). Open columns (bottom)
show the fractional doses injected sc at 15 min intervals.
mice for determination of drug levels. Blood sam-
pling was devised such that no more than a total of
two blood samples (plus a final one just prior to
killing) were drawn from each mouse during the
experiment.
At various intervals, three to six mice per sampling
point were killed for the quantification of remain-
ing organisms per thigh.
Peritonitis model. A standard inoculum of 15-20
times the LD 50 of washed organisms was injected ip
with 3% hog mucin into normal female ICR mice.
Mice were observed and deaths were recorded at
12-hr intervals for at least seven days. Modes of treat-
ment and dosage intervals were exactly as in the thigh
infection model.
Evaluation of results and statistics. Except when
otherwise mentioned, the comparison of antimi-
crobial efficacy of the two modes of drug adminis-
tration was based on experiments performed with
the same bacterial inoculum on the same day and
injected into randomly allotted mice. Results were
evaluated by using the two-tailed t test for unpaired
samples [10].
The LD 50 of P aeruginosa, as determined in the
peritonitis model, and the calculation of the 50%
curative dose (CD 50) were performed according to
Reed and Muench [11].
Results
Granulocytopenia. Previous studies had shown
that cyclophosphamide, given at doses used in the
main experiments, resulted in complete agranulocy-
tosis and left <50 granulocytes/mm 3 in peripheral
blood [2]. In main experiments, we checked for
granulocytopenia in blood smears from 5-10 mice
chosen at random. No more than three granulocytes
per smear could be found in such samples.
Efficacy studies with p-lactam drugs in the thigh
infection model. Figure 1 shows the method of
simulating human pharmacokinetics and also the
impact of drug kinetics (half-life in mice vs. simu-
lated human model) on the efficacy of ticarcillin
against P. aeruginosa.
A single-bolus injection of 1,000 mg of ticarcil-
lin/kg resulted in peak plasma levels (drawn at 15
min after injection) of 610 peg/ml. At N2 hr after bo-
lus injection, ticarcillin levels fell below the MIC for
P. aeruginosa A10 (32 pg/m1). Fractional dosing of
ticarcillin resulted in a simulated half-life of 71 min,
and measurable drug levels were found up to 6 hr
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after starting the treatment. Areas under the curve
(AUCs) were similar for both modes of dosing (529
and 538 pig hr/ml after bolus injection and fractional
dosing, respectively).
In saline-treated control mice, P aeruginosa A10
grew at a log linear rate. An inoculum of ,--‘, 107 cfu
invariably killed normal mice between 12 and 24 hr
after infection, and all untreated granulocytopenic
mice were killed by the infection shortly after 12 hr.
In normal mice, we found a small but statistically
significant (P < .05) superiority of drug plasma ki-
netics over a single bolus injection in the simulated
human model. Breakthrough growth did not occur,
although plasma drug levels fell below the MIC at
2.5 and 4.8 hr after bolus injection and initiation of
simulated human kinetics, respectively.
In granulocytopenic mice (figure 1), plasma drug
kinetics clearly dictated not only the time course of
the bactericidal effect but equally the therapeutic
outcome. After bolus injection, significant (P < .001)
bacterial regrowth occurred as soon as the ticarcil-
lin level fell below the MIC, whereas no such break-
through was observed in mice treated with this drug
by simulated human kinetics. Almost identical re-
sults to those shown in figure 1 were obtained in con-
firming experiments with P aeruginosa strain ATCC
27853 treated with ticarcillin (1,000 mg/kg).
The activity of ceftazidime (250 mg/kg in granu-
locytopenic mice) against P aeruginosa ATCC 27853
was determined in an additional set of experiments
(figure 2). As found with ticarcillin, the superiority
of simulated human kinetics over bolus injection was
highly significant.
Additional experiments were performed with cef-
triaxone. A poorly ceftriaxone-susceptible P aeru-
ginosa strain (A10; MIC, 16 pig/m1) and a highly sus-
ceptible E. coli (ATCC 25922; MIC, 0.5 pig/m1) were
chosen as target organisms (figure 3). Each mouse
was infected with P aeruginosa in one thigh and with
E. coli in the opposite thigh. A total dose of ceftri-
axone was chosen that, with both modes of drug ad-
ministration and throughout the duration of the ex-
periment, guaranteed drug levels above the MIC for
E. coli but not for that of P aeruginosa after bolus
injection. As shown in figure 3, the time course of
the antimicrobial effect against E. coli ATCC 25922
was identical for both modes of dosing, a result in-
dicating that the activity of this drug was mainly de-
termined by the aggregate time the levels of this drug
stayed above the MIC for the target organisms.
P aeruginosa was also similarly affected by both
Figure 2. Human vs. murine plasma kinetics of ceftazi-
dime and activity on P. aeruginosa ATCC 27853 in
granulocytopenic mice. Plasma levels fell below the MIC
(2 pig/m1) by ,‘,3 and 7 hr after bolus and fractional dos-
ing, respectively. See figure 1 for explanation of symbols.
modes of dosing during the first 4 hr of treatment.
In sharp contrast to E. coli, however, P aeruginosa
started to regrow in mice treated by bolus injection
of the drug. This breakthrough growth could well
be explained by the fact that, 4 hr after bolus injec-
tion, the drug levels fell below the MIC. Approxi-
mated human pharmacokinetics of ceftriaxone, on
the other hand, prevented drug levels falling below
the MIC and, as a consequence, prevented bacterial
breakthrough growth.
Efficacy studies with aminoglycosides in the thigh
infection model. The impact of plasma kinetics on
the activity of gentamicin against P aeruginosa in
vivo is shown in figure 4. Again, normal and granu-
locytopenic host animals were studied. Gentamicin
(32 mg/kg) injected in decreasing fractional doses
was used to approximate peak plasma levels and ki-
netics as obtained after maximal dosing in man. This
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Figure 3. Human vs. murine plasma kinetics of ceftri-
axone and activity against E. coli and P. aeruginosa. See
figure 1 for explanations of symbols.
regimen was thus compared with that in which 32
mg/kg was given as a single-bolus injection.
Bolus injection of gentamicin resulted in peak
plasma levels that exceeded the MIC for the target
organisms (8 pg/m1) for ,‘, 1.5 hr followed by a half-
life (based on plasma levels of the first 2 hr) of 20.4
min. A long A phase was observed. In contrast, frac-
tional dosing of the same total amount of drug led
to a simulated half-life of 112 min. The total AUC
was 35.8 mg hr/ml and 42.6 mg hr/ml aftef bolus
and fractional dosing, respectively.
The time course of the bactericidal effect of the
two dosing modes of gentamicin differed substan-
tially from the one previously obtained with (3-lac-
tams. In normal and in granulocytopenic mice, bo-
lus injection was significantly more effective at 1 and
2 hr of treatment (P < .01). Later on, however, this
difference became considerably smaller. Repeated ex-
periments were necessary to demonstrate a signifi-
cant difference (P < .0125) in normal mice when the
drug-isodose point (8 hr) was reached, i.e., the time
when equal total amounts of gentamicin had been
injected in both groups of mice. On the other hand,
in granulocytopenic animals no superiority of the
bolus injection could be demonstrated by the time
the isodose point was reached. This loss of superi-
ority was mainly due to late breakthrough growth
of the target organisms.
A series of confirming experiments was performed
with netilmicin and three strains of P aeruginosa.
Again the effect of approximated human plasma
kinetics of the study drug (obtained by decreasing
fractional doses) was compared with the effect of
a single bolus injection. Results obtained in granu-
locytopenic mice are shown in figure 5.
Netilmicin exhibited a clear gentamicin-type re-
sponse. As with gentamicin, the time course of the
bactericidal effect was markedly dependent on peak
plasma levels (superiority of bolus injections after
1 hr of treatment). At the isodose point, however,
both modes of treatment proved to be equally effec-
tive in all three strains tested.
Efficacy studies in the mouse peritonitis model.
Focusing on ticarcillin, ceftazidime, and netilmicin
and on P aeruginosa ATCC 27853, the mouse perito-
nitis model was used to further assess the impact of
bolus vs. simulated human kinetics on antimicrobial
efficacy. Mice were infected with 15 to 20 LD50 (5
x 10' cfu/ml) ip. One hour later groups of 12 mice
were treated with drug doses that varied from an in-
effective to a 100% effective (i.e., death-preventing)
dose. In the very same experiment each dose was
given as a single bolus injection in one group of mice
vs. fractional doses of the same total amount of drug
resulting in approximated human plasma kinetics in
a comparative group.
In contrast to netilmicin, ticarcillin (<900 mg/kg)
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was unable to prevent death of infected animals when
a single-bolus injection or a single course of frac-
tional doses was given. Similarly, ceftazidime (1,000
mg/kg) had no death-preventing effect when injected
as one bolus and saved only 33% of infected animals
when administered in decreasing fractional doses
over 8 hr. Therefore, two bolus injections of ticarcil-
lin and ceftazidime were compared with two courses
of fractional dosing over 6 hr and 8 hr, respectively.
Results are listed in table 1. Clearly, as shown before
in the thigh infection model, ticarcillin and ceftazi-
dime were significantly more effective when ad-
ministered in fractional doses (simulated human
plasma kinetics). In contrast, bolus injections proved
to be superior to fractional doses of netilmicin.
Moreover, animals that died after treatment with
(3-lactams did so significantly earlier when treated
by conventional methods than when treated by simu-
lated human pharmacokinetics. On the other hand,
netilmicin-treated mice died later when treated by
conventional bolus injection rather than by simulated
human pharmacokinetics.
Drug kinetics of single bolus injections and sin-
gle 6- to 8-hr courses of simulated human kinetics
were studied in separate experiments. The time af-
ter starting the treatment was calculated when drug
concentrations fell below the MIC level for the tar-
get organism. After bolus injection and fractional
dosing, respectively, this time was 2 and 5 hr for ticar-
cillin (900 mg/kg), 2 and 8 hr for ceftazidime (250
mg/kg), and <1 hr for both modes of treatment with
netilmicin (6.7 mg/kg).
Discussion
In two animal models, we clearly demonstrated the
relation between half-life and antimicrobial activity
of various drugs. In normal and granulocytopenic
mice, a given dose of a fl-lactam drug (ticarcillin,
ceftazidime, or ceftriaxone) had a poor effect on
P aeruginosa when injected as a single bolus. In con-
trast, a highly significant superiority was found when
the same total amount of these drugs was subdivided
and administered in fractional doses so that human
plasma kinetics were approximated. On the other
hand, two aminoglycosides (gentamicin and netil-
micin) proved to be equally or even more effective
when administered as a bolus injection than when
human pharmacokinetics were approximated with
an identical amount of these drugs. Thus, in vivo,
the activity of gentamicin and netilmicin was more
Figure 4. Human vs. murine plasma kinetics of gen-
tamicin and activity in normal and granulocytopenic mice
against P. aeruginosa strain A10. Mean values 1 SD
from three to 12 animals per data point.
likely to be peak-level dependent, whereas the ac-
tivity of ticarcillin, ceftazidime, and ceftriaxone de-
pended mainly on the time of persisting drug levels.
It is most evident that both dose and half-life,
which mainly determine the AUC of a parenterally
given drug, are of key importance for the activity
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Figure 5. Human vs. murine plasma kinetics of netil-
micin and activity against three different strains of
P. aeruginosa in granulocytopenic mice. Bars represent
geometric means of three to 12 mice ± SD of the A — log
from cfu/thigh level at start of treatment (total dose, 28
mg/kg): hatched bars, bolus injection (peak level of 32.9
± 6µg/ml followed by a half-life of 22.1 min); dotted
bars, fractional dosing resulting in peak levels of 10.4 ±
1.71Ag/m1 followed by a half-life of 119 min; open bars,
untreated controls. Standard MICs were 4, 8, and 8 pg/m1
for strain ATCC 27853, 14974, and A10, respectively.
of an antibiotic in vivo. The present study demon-
strates that in addition to the AUC per se it is the
shape of the AUC that may have a considerable im-
pact on antimicrobial activity in vivo. Moreover, the
effect of the shape of the AUC (ESAUC) proved to
depend on the drug in question. This finding in turn
most likely relates to the mechanism of action and
more specifically to the shape of the dose-response
curve of the drugs. We have previously shown that
the bactericidal effect of gentamicin and netilmicin
on Pseudomonas is fast and drug-concentration de-
pendent in vitro as well as in our animal model [12].
The dose-response curve of gentamicin on Pseudo-
monas had no ceiling [12, 13]. In contrast, the bac-
tericidal effect of various fl-lactam drugs against
P aeruginosa clearly had an upper limitation that
was close to the MIC, i.e., the bactericidal activity
of 13-lactams was not dose dependent in concentra-
tions above the MIC [14]. Those findings indicate
that — in contrast to aminoglycosides — any dosing
and dosage schedule of fl-lactam drugs that results
in high-spiking blood levels far above the MIC for
short periods of time is actually wasting the drug.
Preliminary results of ongoing studies in our lab-
oratory indicate that the difference in ESAUC be-
tween ticarcillin, ceftazidime, and ceftriaxone, on one
hand, and gentamicin and netilmicin, on the other
hand, is characteristic for j3-lactam drugs (ticarcillin-
type response) and aminoglycosides (gentamicin-
type response) in general. Moreover, on the basis of
extended previous work with the same study organ-
isms [14], we postulate that the ESAUC can be de-
rived, at least in part, from in vitro time-kill and
regrowth curves and from in vitro concentration-
response curves of a given combination of drug and
organism [14].
The results of our present study are in full agree-
ment with results of previous investigations by both
ourselves and others. On the basis of sound ex-
perimental work it has been postulated that the ac-
tivity of j3-lactam drugs on organisms other than
Pseudomonas depends also on the aggregate time
the drug level stays above the MIC [15, 16]. In addi-
tion, no substantial postantibiotic effect (PAE; i.e.,
suppression of bacterial growth after removal of the
drug) could be demonstrated for /3-lactam drugs
against gram-negative organisms [17]. This lack of
a PAE may be an additional factor that explains the
poor efficacy of bolus injections of P-lactam antibi-
otics in the present study. On the other hand, ami-
noglycosides have been shown to exhibit a PAE of
up to 2 hr on P aeruginosa in vitro and in vivo [2,
13, 17]. Thus, the PAE may cover, at least in part,
the dosage interval and prevent bacterial break-
through growth.
In the present study, a PAE was again observed
after bolus injection of gentamicin. However, in
granulocytopenic animals, this PAE was not long
enough to prevent regrowth of the target organisms
up to the isodose point. On the other hand, no break-
through growth was observed in normal animals.
This difference between granulocytopenic and nor-
mal mice can well be explained by results of recent
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Table 1. Impact of dosage schedule on CD s0 of three
drugs against P. aeruginosa ATCC 27853 in mice.
CD50
Bolus injection
	 Fractional dosing
2 x 750 mg/kg 	 2 x 450 mg/kg
2 x 550 mg/kg 	 2 x 250 mg/kg
1 x 6 mg/kg 	 1 x 13.4 mg/kg
studies. A synergistic effect of various antibiotics and
the activity of granulocytes has been demonstrated
[18, 19]. In addition, a so-called postantibiotic leu-
kocyte effect has recently been described for some
drugs [20], i.e., an enhanced susceptibility of drug-
preexposed organisms to killing and phagocytosis
by granulocytes. Thus, in normal, as opposed to
granulocytopenic hosts, breakthrough growth of bac-
teria may be suppressed by granulocyte synergy be-
low the MIC and postantibiotic leukocyte effect.
There is no question that due to ease of handling
and economic aspects, mice and rats must remain
the chief experimental animals for preclinical studies.
We have to consider, however, that because of the
very active metabolism and the very short half-life
of antimicrobial agents in small animals, results ob-
tained with any test substance in such animal models
cannot easily be scaled up to man, even if the differ-
ence regarding pharmacokinetics is taken into ac-
count. Rather, it should be kept in mind that —
besides the AUC — the shape of the AUC is a rele-
vant additional factor that determines the pharmaco-
logical response to antimicrobial agents and proba-
bly to any other test substance in vivo. We believe,
therefore, that misleading results may be obtained
if a biologically active substance is tested in small
animals only after injections at intervals of many
hours, similar to those used in man. Since the extent
and even the quality of the ESAUC is different for
different drugs with different dose-response curves,
caution must be urged, especially for comparisons
of drugs so performed.
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